文献速递肿瘤 PET/CT

葡萄糖代谢影像组学特征可预测套细胞淋巴瘤结局

Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-07-08

该回顾性研究纳入107例未经治疗的套细胞淋巴瘤患者,基于治疗前[18F]FDG PET/CT提取代谢肿瘤体积的影像组学特征,评估其对2年无进展生存(PFS)的预测价值。结果显示SUVmean与Entropy可显著预测2年PFS,联合临床/实验室/生物学数据后AUC提升,代谢风险联合MIPI-b可优化PFS预后分层。

要点

  • SUVmean与Entropy是2年PFS的独立预测因子
  • 高代谢风险(SUVmean>3.55且Entropy>3.5)提示预后更差
  • MIPI-b联合代谢风险可实现最佳PFS预后分层

核心结论

  • 在套细胞淋巴瘤中,[18F]FDG PET/CT衍生的影像组学特征SUVmean和Entropy可能改善2年PFS预测和PFS预后评估。
  • 联合代谢、临床、实验室和生物学参数可能获得最佳预测效果。

研究设计与样本

  • 回顾性研究纳入107例未经治疗、计划接受CD20抗体免疫(化学)治疗的套细胞淋巴瘤患者。
  • 从治疗前[18F]FDG PET/CT的代谢肿瘤体积中提取SUV、总病变糖酵解和16个共现矩阵影像组学特征。
  • 采用多层感知器神经网络联合逻辑回归进行特征选择以预测2年PFS,并计算MIPI和MIPI-b与影像组学数据联合。
  • 使用Kaplan-Meier估计和log-rank检验进行PFS预后评估。

主要发现

  • SUVmean(OR 1.272,P=0.013)和Entropy(OR 1.131,P=0.027)可显著预测2年PFS。
  • 仅基于两个影像组学特征的中位AUC为0.72,加入临床/实验室/生物学数据后为0.82。
  • 高SUVmean联合高Entropy(SUVmean>3.55且Entropy>3.5)与更差预后相关(中位PFS 20.3 vs. 39.4个月,HR 2.285,P=0.005)。
  • MIPI-bm(MIPI-b联合代谢风险)获得最佳PFS预后分层:低危、中危和高危组中位PFS分别为43.2、38.2和20.3个月(P=0.005)。

关键数值与推荐

  • SUVmean>3.55且Entropy>3.5定义为高代谢风险。
  • MIPI-bm联合模型将患者分为低危、中危和高危组,中位PFS分别为43.2、38.2和20.3个月(P=0.005)。

临床怎么用

  • 治疗前[18F]FDG PET/CT影像组学特征可用于套细胞淋巴瘤患者的2年PFS风险分层。
  • 联合SUVmean、Entropy与MIPI-b有助于识别高危患者,可能指导个体化治疗决策。

局限性

  • 回顾性研究设计可能引入选择偏倚。
  • 样本量有限(107例),需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether [18F]FDG PET/CT-derived radiomic features alone or in combination with clinical, laboratory and biological parameters are predictive of 2-year progression-free survival (PFS) in patients with mantle cell lymphoma (MCL), and whether they enable outcome prognostication. METHODS: Included in this retrospective study were 107 treatment-naive MCL patients scheduled to receive CD20 antibody-based immuno(chemo)therapy. Standardized uptake values (SUV), total lesion glycolysis, and 16 co-occurrence matrix radiomic features were extracted from metabolic tumour volumes on pretherapy [18F]FDG PET/CT scans. A multilayer perceptron neural network in combination with logistic regression analyses for feature selection was used for prediction of 2-year PFS. International prognostic indices for MCL (MIPI and MIPI-b) were calculated and combined with the radiomic data. Kaplan-Meier estimates with log-rank tests were used for PFS prognostication. RESULTS: SUVmean (OR 1.272, P = 0.013) and Entropy (heterogeneity of glucose metabolism; OR 1.131, P = 0.027) were significantly predictive of 2-year PFS: median areas under the curve were 0.72 based on the two radiomic features alone, and 0.82 with the addition of clinical/laboratory/biological data. Higher SUVmean in combination with higher Entropy (SUVmean >3.55 and entropy >3.5), reflecting high "metabolic risk", was associated with a poorer prognosis (median PFS 20.3 vs. 39.4 months, HR 2.285, P = 0.005). The best PFS prognostication was achieved using the MIPI-bm (MIPI-b and metabolic risk combined): median PFS 43.2, 38.2 and 20.3 months in the low-risk, intermediate-risk and high-risk groups respectively (P = 0.005). CONCLUSION: In MCL, the [18F]FDG PET/CT-derived radiomic features SUVmean and Entropy may improve prediction of 2-year PFS and PFS prognostication. The best results may be achieved using a combination of metabolic, clinical, laboratory and biological parameters.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Mayerhoefer ME, Riedl CC, Kumar A, et al. Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma. Eur J Nucl Med Mol Imaging. 2019. PMID: 31286200. doi:10.1007/s00259-019-04420-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。